MCID: PST029
MIFTS: 38

Postmenopausal Atrophic Vaginitis

Categories: Reproductive diseases

Aliases & Classifications for Postmenopausal Atrophic Vaginitis

MalaCards integrated aliases for Postmenopausal Atrophic Vaginitis:

Name: Postmenopausal Atrophic Vaginitis 12 15 71 32
Atrophic Vaginitis 12 74 17
Senile Vaginitis 12

Classifications:



External Ids:

Disease Ontology 12 DOID:11968
ICD9CM 34 627.3
SNOMED-CT 67 52441000
ICD10 32 N95.2
UMLS 71 C0156409

Summaries for Postmenopausal Atrophic Vaginitis

Disease Ontology : 12 A vaginitis that occurs in postmenopausal women and is characterized by vaginal atrophy secondary to estrogen deficiency.

MalaCards based summary : Postmenopausal Atrophic Vaginitis, also known as atrophic vaginitis, is related to vaginal discharge and osteoporosis. An important gene associated with Postmenopausal Atrophic Vaginitis is SHBG (Sex Hormone Binding Globulin), and among its related pathways/superpathways are Nongenotropic Androgen signaling and Lamotrigine Pathway, Pharmacokinetics and Pharmacodynamics. The drugs Apricot and Estrogens have been mentioned in the context of this disorder. Affiliated tissues include breast, bone and ovary, and related phenotype is renal/urinary system.

Wikipedia : 74 Atrophic vaginitis is inflammation of the vagina as a result of tissue thinning due to not enough... more...

Related Diseases for Postmenopausal Atrophic Vaginitis

Diseases related to Postmenopausal Atrophic Vaginitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 91)
# Related Disease Score Top Affiliating Genes
1 vaginal discharge 28.6 OXT GNRH1 ESR1 CYP19A1
2 osteoporosis 27.9 SHBG OXT GNRH1 ESR1 CYP19A1
3 vaginitis 10.4
4 androgen insensitivity, partial 10.2 SHBG CYP19A1
5 alopecia, androgenetic, 1 10.2 SHBG CYP19A1
6 complete androgen insensitivity syndrome 10.2 SHBG CYP19A1
7 atrophic vulva 10.2 SHBG ESR1
8 androgenic alopecia 10.2 SHBG CYP19A1
9 acute cystitis 10.1
10 mixed cerebral palsy 10.1 SHBG GNRH1
11 mammographic density 10.1 ESR1 CYP19A1
12 gender identity disorder 10.1 ESR1 CYP19A1
13 steroid inherited metabolic disorder 10.1 SHBG GNRH1
14 juvenile nasopharyngeal angiofibroma 10.1 ESR1 CYP19A1
15 hypertrophy of breast 10.0 ESR1 CYP19A1
16 cervical polyp 10.0
17 vulvitis 10.0
18 pelvic varices 10.0 SHBG GNRH1
19 infertility due to extratesticular cause 10.0 GNRH1 ESR1
20 sebaceous gland disease 10.0 SHBG GNRH1
21 prostatic hypertrophy 10.0 ESR1 CYP19A1
22 inhibited male orgasm 10.0 SHBG OXT
23 precocious puberty 10.0 GNRH1 CYP19A1
24 adenomyoma 9.9 GNRH1 ESR1
25 premature menopause 9.9 GNRH1 CYP19A1
26 breast neuroendocrine neoplasm 9.9 GNRH1 ESR1
27 luminal breast carcinoma 9.9 ESR1 CYP19A1
28 ovarian cyst 9.9 GNRH1 CYP19A1
29 breast cancer 9.9
30 pelvic organ prolapse 9.9
31 bone mineral density quantitative trait locus 8 9.9
32 bone mineral density quantitative trait locus 15 9.9
33 endometrial hyperplasia 9.9
34 squamous cell carcinoma 9.9
35 47,xyy 9.9
36 pigmentation disease 9.9 SHBG OXT
37 bone resorption disease 9.9 SHBG ESR1 CYP19A1
38 estrogen-receptor negative breast cancer 9.8 ESR1 CYP19A1
39 luteoma 9.8 SHBG GNRH1 CYP19A1
40 breast juvenile papillomatosis 9.8 OXT ESR1
41 breast fibroadenoma 9.8 ESR1 CYP19A1
42 infertility 9.8 SHBG GNRH1 CYP19A1
43 premature ejaculation 9.8 OXT CYP19A1
44 ovarian hyperstimulation syndrome 9.8 SHBG GNRH1 CYP19A1
45 anovulation 9.8 SHBG GNRH1 CYP19A1
46 stuttering 9.8 SHBG GNRH1 CYP19A1
47 lipoid congenital adrenal hyperplasia 9.8 SHBG GNRH1 CYP19A1
48 amenorrhea 9.8 SHBG GNRH1 CYP19A1
49 hyperandrogenism 9.8 SHBG GNRH1 CYP19A1
50 mild pre-eclampsia 9.8 OXT ESR1

Comorbidity relations with Postmenopausal Atrophic Vaginitis via Phenotypic Disease Network (PDN):


Acute Cystitis Anxiety
Deficiency Anemia Female Stress Incontinence
Hypertension, Essential Hypothyroidism
Osteoporosis

Graphical network of the top 20 diseases related to Postmenopausal Atrophic Vaginitis:



Diseases related to Postmenopausal Atrophic Vaginitis

Symptoms & Phenotypes for Postmenopausal Atrophic Vaginitis

MGI Mouse Phenotypes related to Postmenopausal Atrophic Vaginitis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 renal/urinary system MP:0005367 9.02 CYP19A1 ESR1 GNRH1 OXT POLR3A

Drugs & Therapeutics for Postmenopausal Atrophic Vaginitis

Drugs for Postmenopausal Atrophic Vaginitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 56)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Apricot Approved Phase 4
2 Estrogens Phase 4
3 Hormone Antagonists Phase 4
4 Hormones Phase 4
5 Estrogens, Conjugated (USP) Phase 4
6
Megestrol acetate Approved, Investigational, Vet_approved Phase 3 595-33-5 11683
7
Polyestradiol phosphate Approved Phase 3 28014-46-2
8
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757
9 Pycnogenols Phase 3
10 Antineoplastic Agents, Hormonal Phase 3
11 Central Nervous System Stimulants Phase 3
12
Megestrol Phase 3 3562-63-8 19090 3080587
13 Contraceptives, Oral Phase 3
14 Appetite Stimulants Phase 3
15 Estradiol 17 beta-cypionate Phase 3
16 Contraceptive Agents Phase 3
17 Estradiol 3-benzoate Phase 3
18
Echinacea Approved, Experimental Phase 1, Phase 2
19
Oxytocin Approved, Vet_approved Phase 2 50-56-6 439302 53477758
20
Loperamide Approved Phase 2 53179-11-6 3955
21
Calcium polycarbophil Approved Phase 2 126040-58-2
22
Caffeine Approved Phase 2 58-08-2 2519
23
Progesterone Approved, Vet_approved Phase 2 57-83-0 5994
24
Methyltestosterone Approved Phase 1, Phase 2 58-18-4 6010
25
Testosterone Approved, Experimental, Investigational Phase 1, Phase 2 58-22-0, 481-30-1 6013 10204
26
Testosterone undecanoate Approved, Investigational Phase 1, Phase 2 5949-44-0
27
Testosterone enanthate Approved Phase 1, Phase 2 315-37-7 9416
28
Calcium Approved, Nutraceutical Phase 2 7440-70-2 271
29 Gotu Kola Phase 1, Phase 2
30 Omega 3 Fatty Acid Phase 2
31 Oxytocics Phase 2
32 Calcium, Dietary Phase 2
33 Cathartics Phase 2
34 Gastrointestinal Agents Phase 2
35 Laxatives Phase 2
36 Psyllium Phase 2
37 Antidiarrheals Phase 2
38 Progestins Phase 2
39 Anabolic Agents Phase 1, Phase 2
40 Testosterone 17 beta-cypionate Phase 1, Phase 2
41 Emollients Phase 1, Phase 2
42 Androgens Phase 1, Phase 2
43
Thrombin Approved, Investigational Phase 1
44 Angelica Phase 1
45 Dong Quai Phase 1
46 Acidophilus Phase 1
47 Mitogens Phase 1
48
Hyaluronic acid Approved, Vet_approved 9004-61-9 53477741
49
Letrozole Approved, Investigational 112809-51-5 3902
50
Anastrozole Approved, Investigational 120511-73-1 2187

Interventional clinical trials:

(show all 44)
# Name Status NCT ID Phase Drugs
1 The Effects of Vaginal Estrogen and a Nonhormonal Alternative on the Vaginal and Urinary Microbiome in Women With Genitourinary Syndrome of Menopause: A Randomized Controlled Trial Unknown status NCT02869165 Phase 4 Premarin vaginal cream;Apricot kernel oil
2 Oral Low-molecular Weight Hyaluronic Acid in the Treatment of Atrophic Vaginitis Completed NCT02014428 Phase 4 Placebo
3 IMPLORE Study: Investigation of Microbiomes of Postmenopausal Women Looking for Outcomes and Response to Estrogen Therapy Recruiting NCT03996603 Phase 4 Conjugated Estrogens Cream
4 The Impact of HIV on Accelerated Aging in the Female Genital Tract: a Pilot Trial of Topical Estradiol to Improve the Vaginal Microbiome and Symptoms of Vaginal Atrophy in Menopausal Women With HIV Not yet recruiting NCT04079218 Phase 4 Estradiol Vaginal Insert
5 A 12 Month Double-blind, Randomized, Parallel-group, Placebo-controlled, Multi-center Trial to Investigate the Efficacy and Safety of Vagifem Low Dose (10 mcg 17beta-estradiol Vaginal Tablet) for the Treatment of Postmenopausal Atrophic Vaginitis Symptoms Completed NCT00108849 Phase 3 estradiol, 10 mcg
6 Efficacy and Safety of 2 Low-Dose Regimens of Conjugated Estrogen Cream Administered Vaginally in Postmenopausal Women With Atrophic Vaginitis Completed NCT00137371 Phase 3 PVC (daily for 21 days, 7 days off);PVC (twice weekly)
7 Evaluation of Safety and Efficacy of 17-Beta Estradiol in Treatment of Estrogen Deficiency-Derived Atrophic Vaginitis Completed NCT00464971 Phase 3 estradiol, 25 mcg
8 Study to Evaluate the Therapeutic Equivalence of Estradiol Vaginal Cream, 0.01% to Estrace® Estradiol Vaginal Cream 0.01% in Atrophic Vaginitis Completed NCT03294538 Phase 3 Estrace® Cream;Generic Estradiol Cream;Vehicle Cream
9 Clinical Endpoint Therapeutic Equivalence Multi-Site Study Comparing Estradiol Vaginal Cream (0.01%; Alvogen Pine Brook LLC.) to Estrace® Cream (0.01%; Warner Chilcott) in Postmenopausal Females With Atrophic Vaginitis Completed NCT02995694 Phase 3 Estradiol;Placebos;Reference
10 A 12 Month, Open-label, Multi-center Trial to Investigate the Endometrial Safety of Vagifem Low Dose (10ug 17beta-estradiol Vaginal Tablet) in Postmenopausal Women With Atrophic Vaginitis Symptoms Completed NCT00431132 Phase 3 estradiol, 10 mcg
11 Clinical Endpoint Therapeutic Equivalence Multi-Site Study Comparing Estradiol Vaginal Cream (0.01%; Mylan) to Estrace® Cream (0.01%; Warner Chilcott) in Postmenopausal Females With Atrophic Vaginitis Completed NCT02195986 Phase 3 Estradiol Vaginal Cream, 0.01%;Estrace® 0.01% cream;Placebo Vaginal Cream
12 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Comparing the Efficacy and Safety of 17-Beta Estradiol 10 Micrograms and 25 Micrograms (Vagifem) Doses in Treatment of Estrogen Deficiency-Derived Atrophic Vaginitis Completed NCT00465192 Phase 3 estradiol, 10 mcg;estradiol, 25 mcg;placebo
13 An Investigator-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Bioequivalence of Estradiol Vaginal Inserts, USP 10 mcg and Vagifem® (Estradiol Vaginal Tablets) 10 mcg and Compare Both Active Treatments to a Placebo Control in Female Subjects With Moderate to Severe Symptoms of Vulvar and Vaginal Atrophy Associated With Menopause Completed NCT01779947 Phase 3 Estradiol Vaginal Tablets 10 mcg;placebo
14 Intravaginal Prasterone (DHEA) Against Vulvovaginal Atrophy Associated With Menopause Completed NCT02013544 Phase 3 Placebo;Prasterone (DHEA)
15 Dehydroepiandrosterone (DHEA) Against Vaginal Atrophy Completed NCT01358760 Phase 3 Placebo;DHEA;DHEA
16 DHEA Against Vaginal Atrophy - Safety Study of 12 Months Completed NCT01256671 Phase 3 DHEA
17 DHEA Against Vaginal Atrophy (Placebo-controlled, Double-blind and Randomized Phase III Study of 3-month Intravaginal DHEA) Completed NCT01256684 Phase 3 Placebo;DHEA;DHEA
18 The Effects of Local Vaginal Estrogen in Postmenopausal Women With Pelvic Organ Prolapse: A Randomized Control Trial Completed NCT00803335 Phase 3 Vaginal conjugated estrogen cream 0.5gm;Vaginal conjugated estrogen cream 1.0gm
19 Topical DHEA Against Vaginal Atrophy (3-Month Placebo-Controlled Double-Blind Randomized Phase III Study) Completed NCT01846442 Phase 3 Placebo;DHEA (0.25%);DHEA (0.5%);DHEA (1.0%)
20 A Phase III Trial of Placebo Versus Megestrol Acetate 20 MG/Day Versus Megestrol Acetate 40 MG/Day as Treatment for Symptoms of Ovarian Failure in Women Treated for Breast Cancer: SWOG Study S9626 Completed NCT00005975 Phase 3 Megestrol Acetate 20mg/day;Megestrol Acetate 40 mg/day;Megestrol Acetate Placebo 20 mg/day;Megestrol Acetate Placebo 40 mg/day
21 A Randomized Controlled Trial to Evaluate the Efficacy of Low Dose Vaginal Estrogens in the Treatment of Atrophic Vaginitis Terminated NCT00816556 Phase 3 Estriol;Estradiol valerate;Vanicream Lite
22 EFFICACY AND SAFETY OF SPIL'S ESTRADIOL VAGINAL TABLET, 10 MCG ESTRADIOL IN SUBJECTS WITH VULVAR AND VAGINAL ATROPHY: A RANDOMIZED, OBSERVER BLIND, PARALLEL GROUPS, ACTIVE AND PLACEBO CONTROLLED, CLINICAL ENDPOINT BIOEQUIVALENCE STUDY Terminated NCT01753102 Phase 3 Estradiol
23 Effect of Intravaginal Prasterone (DHEA) on Moderate to Severe Symptoms of Vulvovaginal Atrophy Due to Menopause, in Women Under Treatment With an Aromatase Inhibitor for Breast Cancer - (Placebo-Controlled, Double Blind and Randomized Phase III Study) Withdrawn NCT03740945 Phase 3 Placebo;Prasterone (DHEA)
24 Phase I-B Study to Evaluate the Safety, Tolerability and Efficacy of IZN-6NVS for the Treatment of Atrophic Vaginitis or Desquamative Inflammatory Vaginitis Completed NCT02313545 Phase 1, Phase 2 IZN-6NVS Cream
25 A Randomized Trial to Explore the Effect of Oral Omega 3 Fatty Acids on Atrophic Vaginitis in Postmenopausal Breast Cancer Survivors Completed NCT02150525 Phase 2
26 A Phase 2b, Double-blind, Randomized, Parallel, Placebo-Controlled, Multiple-Dose Study to Evaluate the 12-week Efficacy of Vagitocin in Postmenopausal Women With Symptoms of Vaginal Atrophy Completed NCT02497547 Phase 2 Oxytocin;Placebo
27 Microbiological Impact of a Cream and the Feeling of Softness and Freshness in the Intimate Area of Women Completed NCT02162160 Phase 2 Placebo
28 REVIVE: Replens Versus Intra-Vaginal Estrogen for the Treatment of Vaginal Dryness on Aromatase Inhibitor Therapy Recruiting NCT01984138 Phase 2 ESTRING;Replens
29 Vaginal Progesterone Versus Placebo for the Treatment of Vaginal Atrophy - a Double Blind Randomized Control Trial Recruiting NCT02460302 Phase 2 Vaginal progesterone;Placebo
30 Vaginal Testosterone Cream For Atrophic Vaginitis in Women Taking Aromatase Inhibitors for Breast Cancer. Suspended NCT01122342 Phase 1, Phase 2 Testosterone propionate
31 The Treatment Effect of Chinese Herbal Compound Ointment on Atrophic Vaginitis Unknown status NCT02733731 Phase 1 Chinese Herbal Compound Ointment;Estriol
32 A Multiple-Dose, Comparative Bioavailability Study of Premarin® Vaginal Cream Versus Premarin® Oral Tablets in Postmenopausal Women With Atrophic Vaginitis. Completed NCT00167921 Phase 1 Premarin® Vaginal Cream;Premarin® oral tablets
33 A Clinical Study of Pharmacokinetics, Efficacy and Safety of Vaginal Application of Lyophilised Lactobacilli and 0.03 mg Estriol (Gynoflor®) on Atrophic Vaginitis in Postmenopausal Breast Cancer Patients Treated With Aromatase Inhibitors Completed NCT01370551 Phase 1 Gynoflor
34 A Pharmacokinetic Randomized Study With a Parallel Group Design to Assess the Extent of Systemic Absorption of Estradiol During Treatment With a 10 µg or 25 µg Estradiol Vaginal Tablet Administered Once Daily for 2 Weeks Followed by 10 Weeks of Twice-Weekly Maintenance Therapy in Postmenopausal Women With Atrophic Vaginitis Completed NCT01486979 Phase 1 estradiol, 10 mcg;estradiol, 25 mcg
35 An Open Randomized Two-Way Cross-Over Comparative Bioavailability Study to Compare the Extent of Systemic Absorption of Estradiol After a Single Dose Treatment With Two 25 mcg Estradiol Vaginal Tablet Formulations Administered in Postmenopausal Women With Vaginal Atrophy Completed NCT01085877 Phase 1 estradiol, 25 mcg;estradiol, 25 mcg
36 Effect of PRP Injection in Releiving of Symptoms of Senile Vaginitis Recruiting NCT03898401 Phase 1
37 Vagifem® Used for the Treatment of Atrophic Vaginitis Due to Oestrogen Deficiency Completed NCT01507454 estradiol, 25 mcg
38 A Randomized Clinical Trial Comparing Vaginal Laser Therapy to Vaginal Estrogen Therapy in Women With Genitourinary Syndrome of Menopause Completed NCT02691936 Estrogens, Conjugated (USP)
39 VR101: A Pilot Study to Evaluate the Preliminary Feasibility and Safety of a Lubricating Intravaginal Ring to Relieve the Symptoms of Vaginal Dryness Completed NCT02029053 Early Phase 1
40 Hyaluronate for the Treatment and Prevention of Recurrent Urinary Tract Infection in Women Suffering Atrophic Vaginitis Recruiting NCT03981458
41 A Review on the Outcome of Patient Managed in One Stop Postmenopausal Bleeding Clinic in New Territories East Cluster, NTEC Recruiting NCT03382145
42 Serum Estradiol Levels In Postmenopausal Women With Breast Cancer Receiving Adjuvant Aromatase Inhibitors and Vaginal Estrogen Active, not recruiting NCT00984399 Vagifem® (vaginal 17β-estradiol) questionnaire & menopause symptom checklist
43 LASER and Radiofrequency as Alternative Treatments for Genitourinary Syndrome of Menopause Not yet recruiting NCT04045379 Estriol
44 Laser Treatment of Genito-urinary Syndrome in Women With Breast and Endometrial Cancer and Menopausal Women Not yet recruiting NCT03238053

Search NIH Clinical Center for Postmenopausal Atrophic Vaginitis

Genetic Tests for Postmenopausal Atrophic Vaginitis

Anatomical Context for Postmenopausal Atrophic Vaginitis

MalaCards organs/tissues related to Postmenopausal Atrophic Vaginitis:

40
Breast, Bone, Ovary, Testes, Cervix, Prostate

Publications for Postmenopausal Atrophic Vaginitis

Articles related to Postmenopausal Atrophic Vaginitis:

(show top 50) (show all 196)
# Title Authors PMID Year
1
Noncandidal vaginitis: a comprehensive approach to diagnosis and management. 61
31513780 2020
2
The Safety of Local Hormonal Treatment for Vulvovaginal Atrophy in Women With Estrogen Receptor-positive Breast Cancer Who Are on Adjuvant Aromatase Inhibitor Therapy: Meta-analysis. 61
31522958 2019
3
Critical analysis of methods for assessing genitourinary syndrome of menopause used in clinical trials. 61
31644509 2019
4
A Cross-Sectional Study on the Dermatoses in Postmenopausal Patients at a Rural-Based Tertiary Health Care Center. 61
31543529 2019
5
Prevalence and Risk Factors of Stress Urinary Incontinence Among Perimenopausal Women and Its Influence on Daily Life in Women with Sexual Desire Problem. 61
31346999 2019
6
Plasma cell vulvitis presenting as postmenopausal atrophic vaginitis - a case report. 61
31018733 2019
7
[Experience of application of hormonal and probiotic therapy in the complex treatment of women in peri- and postmenopausal with chronic recurrent bacterial cystitis in the background of vulvovaginal atrophy]. 61
31356015 2019
8
Comparison of the effect of hyaluronic acid and estrogen on atrophic vaginitis in menopausal women: A systematic review. 61
30798700 2019
9
Associations of birth characteristics with perimenopausal disorders: a prospective cohort study. 61
30296955 2019
10
Noninvasive Vaginal Rejuvenation: Radiofrequency Devices. 61
31904331 2019
11
Device-based treatment for vaginal wellness. 61
30475926 2018
12
Association between the vaginal microbiota, menopause status, and signs of vulvovaginal atrophy. 61
30358729 2018
13
2018 European (IUSTI/WHO) International Union against sexually transmitted infections (IUSTI) World Health Organisation (WHO) guideline on the management of vaginal discharge. 61
30049258 2018
14
17β-estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis. 61
30358715 2018
15
Diagnosis and Treatment of Genitourinary Syndrome of Menopause. 61
30170002 2018
16
Application of conjugated estrogen cream in the treatment of postmenopausal atrophic vaginitis. 61
30463825 2018
17
Nephrogenic Adenoma in the Setting of Refractory Labial Agglutination in an Elderly Woman. 61
29489552 2018
18
ACOG Committee Opinion No. 740 Summary: Gynecologic Care for Adolescents and Young Women With Eating Disorders. 61
29794675 2018
19
ACOG Committee Opinion No. 740: Gynecologic Care for Adolescents and Young Women With Eating Disorders. 61
29794682 2018
20
Histologic and Clinical Changes in Vulvovaginal Tissue After Treatment With a Transcutaneous Temperature-Controlled Radiofrequency Device. 61
29701623 2018
21
Tuberculosis of the cervix: An uncommon cause of vaginal discharge in a post-menopausal woman. 61
31044761 2018
22
Role of topical oxytocin in improving vaginal atrophy in postmenopausal women: a randomized, controlled trial. 61
29347848 2018
23
Therapeutic Approaches to Atrophic Vaginitis in Postmenopausal Women: A Systematic Review with a Network Meta-analysis of Randomized Controlled Trials. 61
29765921 2018
24
[Acquired clitoral phimosis causing a periclitoral pseudocyst]. 61
29536840 2018
25
Genital diseases in the mature woman. 61
29566925 2018
26
Vaginitis: Diagnosis and Treatment. 61
29671516 2018
27
[La ménopause et le traitement hormonal de la ménopause : une actualisation]. 61
30320986 2018
28
Genitourinary Syndrome of Menopause: Management Strategies for the Clinician. 61
29202940 2017
29
Chitosan Ascorbate Nanoparticles for the Vaginal Delivery of Antibiotic Drugs in Atrophic Vaginitis. 61
29048359 2017
30
A Dermatologist's Approach to Genitourinary Syndrome of Menopause. 61
28453946 2017
31
Challenges of measuring accurate estradiol levels in aromatase inhibitor-treated postmenopausal breast cancer patients on vaginal estrogen therapy. 61
28805983 2017
32
False-Negative Interpretation of Adenocarcinoma In Situ in the College of American Pathologists Gynecologic PAP Education Program. 61
28301226 2017
33
Study of pruritus vulvae in geriatric age group in tertiary hospital. 61
28442799 2017
34
Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management. 61
27472999 2016
35
Erratum: Effects of low dose estrogen therapy on the vaginal microbiomes of women with atrophic vaginitis. 61
27897166 2016
36
Prevalence and risk factors of urinary incontinence among perimenopausal women in Wuhan. 61
27752911 2016
37
ThermiVa: The Revolutionary Technology for Vulvovaginal Rejuvenation and Noninvasive Management of Female SUI. 61
27382227 2016
38
Genitourinary syndrome of menopause: A new name for an old condition. 61
27327425 2016
39
Vaginal estrogen products in hormone receptor-positive breast cancer patients on aromatase inhibitor therapy. 61
27178335 2016
40
Common Questions About Recurrent Urinary Tract Infections in Women. 61
27035041 2016
41
Effects of low dose estrogen therapy on the vaginal microbiomes of women with atrophic vaginitis. 61
27103314 2016
42
Spontaneous Reproductive Tract Lesions in Aged Captive Chimpanzees. 61
26823448 2016
43
A comparative study of vaginal estrogen cream and sustained-release estradiol vaginal tablet (Vagifem) in the treatment of atrophic vaginitis in Isfahan, Iran in 2010-2012. 61
26958050 2015
44
Transcutaneous Temperature Controlled Radiofrequency for Atrophic Vaginitis and Dyspareunia. 61
27679110 2015
45
Effect of ultra-low-dose estriol and lactobacilli vaginal tablets (Gynoflor®) on inflammatory and infectious markers of the vaginal ecosystem in postmenopausal women with breast cancer on aromatase inhibitors. 61
26223323 2015
46
Does a diagnosis of atrophic vaginitis on Papanicolaou test signify the presence of inflammation? 61
25535962 2015
47
The Recent Review of the Genitourinary Syndrome of Menopause. 61
26357643 2015
48
Female sexual dysfunction. 61
25841603 2015
49
Vaginal estriol-lactobacilli combination and quality of life in endocrine-treated breast cancer. 61
25427450 2015
50
Atrophic vaginitis in breast cancer survivors: a difficult survivorship issue. 61
25815692 2015

Variations for Postmenopausal Atrophic Vaginitis

Expression for Postmenopausal Atrophic Vaginitis

Search GEO for disease gene expression data for Postmenopausal Atrophic Vaginitis.

Pathways for Postmenopausal Atrophic Vaginitis

Pathways related to Postmenopausal Atrophic Vaginitis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.41 SHBG GNRH1
2 10.13 ESR1 CYP2D6
3 9.23 ESR1 CYP19A1

GO Terms for Postmenopausal Atrophic Vaginitis

Biological processes related to Postmenopausal Atrophic Vaginitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 response to steroid hormone GO:0048545 9.26 OXT GNRH1
2 uterus development GO:0060065 9.16 ESR1 CYP19A1
3 androgen metabolic process GO:0008209 8.96 ESR1 CYP19A1
4 response to prostaglandin E GO:0034695 8.62 OXT GNRH1

Molecular functions related to Postmenopausal Atrophic Vaginitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 monooxygenase activity GO:0004497 9.26 CYP2D6 CYP19A1
2 steroid hydroxylase activity GO:0008395 9.16 CYP2D6 CYP19A1
3 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen GO:0016712 8.96 CYP2D6 CYP19A1
4 steroid binding GO:0005496 8.62 SHBG ESR1

Sources for Postmenopausal Atrophic Vaginitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....